News

The U.S. Food and Drug Administration has approved Tecelra for the treatment of adults with unresectable or metastatic synovial sarcoma who have previously received chemotherapy

Jade Biosciences, Inc., a biotech company focused on innovative treatments for autoimmune diseases, has announced the successful completion of an $80 million financing round. This round was led by Fairmount and Venrock Healthcare Capital Partners

Celltrion Healthcare Canada Limited has announced that Steqeyma® (ustekinumab injection) and Steqeyma® I.V. (ustekinumab for injection, solution for intravenous infusion) have been approved by Health Canada.

Kexing Biopharm has secured approval from the European Commission for Apexelsin®, a generic alternative to Abraxane® (nab-paclitaxel) by Bristol Myers Squibb and Celgene. WhiteOak Pharmaceutical B.V. developed Apexelsin®

Alcyone Therapeutics Inc., a biotechnology company specializing in advanced genetic therapies and delivery systems for complex neurological conditions, has announced that the U.S. Food and Drug Administration

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved DARZALEX FASPRO® in combination with bortezomib, lenalidomide, and dexamethasone for use as induction

Georgiamune Inc., a biotechnology company in its clinical stages, has announced the initiation of a Phase 1 trial involving their new drug, GIM-531. This study marks the first human dosing of GIM-531, an oral therapy

Novartis has announced that the FDA has granted Priority Review status to Scemblix® (asciminib) for treating newly diagnosed adults with Philadelphia chromosome-positive chronic myeloid leukemia

Boehringer Ingelheim has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a new indication for SPEVIGO®

Shanghai Junshi Biosciences Co., Ltd., a prominent biopharmaceutical firm focused on innovation, along with its subsidiary TopAlliance Biosciences Inc., has received a positive opinion from the Committee for Medicinal Products